News

Zacks Investment Research on MSN4h
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...
The Globe and Mail5h
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Sarepta Therapeutics (SRPT)
In a report issued on July 2, J.P. Morgan also maintained a Hold rating on the stock with a EUR110.00 price target. According to TipRanks.com, Ear is ranked 0 out of 5 stars with an average return of ...